Moreover, type I IFN receptor deficiency was reported to reduce significantly lupus like disease in a mouse model [30] and IFN-α neutralizing antibodies were shown to prevent the clinical manifestations in a lupus flare murine model [31]. Here, IFNA1 is linked to systemic lupus erythematosus.